It is hoped that the report can raise China's RA standardized diagnosis and treatment level and long-term management level, and improve the quality of life of patients with rheumatic immune diseases.

A total of six new drugs and indications, including those for patients suffering from melanoma, ankylosing spondylitis (a rheumatic immune disease), and non-small cell carcinoma, were approved in China last year.

There were about 290 million patients with cardiovascular diseases in China, including 13 million with stroke, 11 million with coronary heart disease, 5 million with pulmonary heart disease, 4.5 million with heart failure, 2 million with rheumatic heart disease, and 245 million with hypertension, according to the report.